General Information of DTT (ID: TTNVSKA)

DTT Name P2Y purinoceptor 6 (P2RY6) DTT Info
Gene Name P2RY6

Molecule-Related Drug & Molecule List

Molecule-Related Drug List
Molecule Type:
DTT
DTP
DME
Drug Status:
Discontinued Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
1 Clinical Trial Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
GC021109 DMQBEYV Alzheimer disease 8A20 Phase 1 [1]
------------------------------------------------------------------------------------
1 Discontinued Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
INS 316 DMTHMEI Lung cancer 2C25.0 Discontinued in Phase 3 [2]
------------------------------------------------------------------------------------
15 Investigative Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
2MeSATP DMUE0W6 Discovery agent N.A. Investigative [2]
3-phenacyl-UDP DMOLZ65 Discovery agent N.A. Investigative [3]
5BrUTP DMEVRH4 Discovery agent N.A. Investigative [2]
adenosine diphosphate DMFUHKP N. A. N. A. Investigative [2]
INS48823 DMLZFTH Discovery agent N.A. Investigative [4]
MRS2567 DMUJEA9 Discovery agent N.A. Investigative [5]
MRS2578 DMKMPS6 Discovery agent N.A. Investigative [5]
MRS2693 DM2L3CJ Discovery agent N.A. Investigative [6]
MRS2782 DMZSO4R Discovery agent N.A. Investigative [7]
MRS2957 DMROQP6 Discovery agent N.A. Investigative [8]
PSB-0952 DMW19LB Discovery agent N.A. Investigative [9]
RB 2 DMCEFUW Discovery agent N.A. Investigative [9]
Rp-5-OMe-UDPalphaB DM03RIT Discovery agent N.A. Investigative [10]
UDP-beta-S DMMWHAV Discovery agent N.A. Investigative [4]
Up3U DMKQWSB Discovery agent N.A. Investigative [4]
------------------------------------------------------------------------------------
⏷ Show the Full List of 15 Investigative Drug(s)
Molecule Interaction Atlas

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Cloning, functional expression and tissue distribution of the human P2Y6 receptor. Biochem Biophys Res Commun. 1996 May 15;222(2):303-8.
3 Synthesis and structure-activity relationships of uracil nucleotide derivatives and analogues as agonists at human P2Y2, P2Y4, and P2Y6 receptors. J Med Chem. 2006 Nov 30;49(24):7076-87.
4 P2 receptors activated by uracil nucleotides--an update. Curr Med Chem. 2006;13(3):289-312.
5 Diisothiocyanate derivatives as potent, insurmountable antagonists of P2Y6 nucleotide receptors. Biochem Pharmacol. 2004 May 1;67(9):1763-70.
6 Structure-activity relationships of uridine 5'-diphosphate analogues at the human P2Y6 receptor. J Med Chem. 2006 Sep 7;49(18):5532-43.
7 Synthesis and potency of novel uracil nucleotides and derivatives as P2Y2 and P2Y6 receptor agonists. Bioorg Med Chem. 2008 Jun 15;16(12):6319-32.
8 Pyrimidine ribonucleotides with enhanced selectivity as P2Y(6) receptor agonists: novel 4-alkyloxyimino, (S)-methanocarba, and 5'-triphosphate gamma-ester modifications. J Med Chem. 2010 Jun 10;53(11):4488-501.
9 Development of potent and selective inhibitors of ecto-5'-nucleotidase based on an anthraquinone scaffold. J Med Chem. 2010 Mar 11;53(5):2076-86.
10 5-OMe-uridine-5'-O-(alpha-boranodiphosphate), a novel nucleotide derivative highly active at the human P2Y(6) receptor protects against death-receptor mediated glial apoptosis. Neurosci Lett. 2014 Aug 22;578:80-4.